EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice

Junji Furuse iD, Namiki Izumi, Kenta Motomura iD, Yoshitaka Inaba iD, Yoshio Katamura, Yasuteru Kondo iD, Kazuhisa Yabushita, Toshiyuki Matsuoka iD, Katsuaki Motoyoshi, Masatoshi Kudo iD

Cancers · 01.02.2025 · 17 (3) · 479

DOI: 10.3390/cancers17030479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 01.02.2025. Verfasst von Junji Furuse und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eisai Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/objectives: The real-world survival of patients with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib has been explored retrospectively with a small sample size. We conducted a prospective observational 2-year extension study (510 study) of a 1-year observational post-marketing study of lenvatinib (504 study) to evaluate the long-term overall survival (OS) of patients with uHCC treated with lenvatinib and associated factors with a large sample size.

Methods

Patients with uHCC included (July 2018 to January 2019) in the 504 study and who consented were eligible for the 510 study and were followed for up to 3 years after lenvatinib treatment initiation. Using the data from the 504 study and 510 study of the 504 study analysis set, we estimated the OS, the time from the first lenvatinib dose to all-cause death by the Kaplan–Meier method (ClinicalTrials.Gov Registration ID, 504 study: NCT03663114; 510 study: NCT04008082).

Results

The 703 patients included in the analysis were followed for a median period (min, max) of 12.5 months (0.1, 44.8). The median OS (95% confidence interval) was 16.6 months (15.4, 18.5). OS was significantly (p < 0.05) associated with bile duct invasion (hazard ratio [HR]: 1.621), portal vein invasion (HR: 1.365), ≥ 4 intrahepatic lesions (HR: 1.437), extrahepatic lesions (HR: 1.357), Child–Pugh B/C (HR: 1.515), mALBI Grade 2a (HR: 1.331), and Grade ≥ 2b (HR: 1.811).

Conclusions

This large-scale, prospective, real-world study demonstrated a long OS, comparable to that reported in the global Phase III REFLECT trial. More advanced-stage tumors and worse hepatic function have been suggested as OS-associated factors, consistent with previous reports.

Schlagwörter

Stichwörter der Autor:innen

hepatocellular carcinomalenvatiniboverall survivalreal-world practice

Autor:innen und Institutionen

  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan.
  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino 180-8610, Japan.
  • Department of Hepatology, Aso Iizuka Hospital, Iizuka 820-8505, Japan.
  • Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.
  • Department of Gastroenterology, Onomichi General Hospital, Onomichi 722-8508, Japan.
  • Department of Hepatology, Sendai Tokushukai Hospital, Sendai 981-3116, Japan.

ORCID-Profile: Junji Furuse, Kenta Motomura, Yoshitaka Inaba, Yasuteru Kondo, Toshiyuki Matsuoka, Masatoshi Kudo

Förderung

  • Eisai Co., Ltd.

Zitieren

APA

Furuse, J., Izumi, N., Motomura, K., Inaba, Y., Katamura, Y., Kondo, Y., Yabushita, K., Matsuoka, T., Motoyoshi, K., & Kudo, M. (2025). Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice. Cancers, 17(3), 479. https://doi.org/10.3390/cancers17030479

Vancouver

Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, et al. Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice. Cancers. 2025;17(3):479. doi:10.3390/cancers17030479

BibTeX
@article{Furuse2025,
  author = {Furuse, Junji and Izumi, Namiki and Motomura, Kenta and Inaba, Yoshitaka and Katamura, Yoshio and Kondo, Yasuteru and Yabushita, Kazuhisa and Matsuoka, Toshiyuki and Motoyoshi, Katsuaki and Kudo, Masatoshi},
  title = {Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {479},
  doi = {10.3390/cancers17030479}
}
Kostenlos starten →